Syndax Pharmaceuticals (SNDX) investor relations material

Business overview and recent updates

• Transitioned to a commercial-stage oncology business with two marketed products targeting AML/ALL and chronic GVHD, both showing strong initial performance.

• Actively conducting frontline and registration trials for both products, with multiple data readouts expected this year.

• Announced a $250 million five-year convertible debt facility, catalyzed by an unsolicited investor approach, providing low-cost capital and removing financing overhang.

• Capital will support late-stage readouts, early pipeline investments, and upcoming R&D initiatives.

Financial strategy and collaborations

• Operating expenses remain flat, and the company is fully funded with the new debt facility.

• Incyte collaboration splits U.S. R&D costs 45/55 (Syndax/Incyte); Incyte covers all ex-U.S. development and regulatory expenses.

• Convertible debt was specifically sought by the investor, not equity.

R&D day and pipeline outlook

• Upcoming R&D day will provide updates on lifecycle management for revumenib, axatilimab, and early-stage oncology assets.

• Phase II IPF and frontline GVHD readouts are expected in Q4, with accelerated timelines due to strong enrollment.

• Early-stage pipeline updates will highlight targeted precision oncology agents.